Results 11 to 20 of about 23,309 (224)

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics [PDF]

, 2018
Tamoxifen reduces the rate of breast cancer recurrence by about one-half. It is converted to more active metabolites by enzymes encoded by polymorphic genes, including cytochrome P450 2D6 (CYP2D6) and transported by ATP-binding cassette transporters. Genetic polymorphisms that confer reduced CYP2D6 activity or concurrent use of CYP2D6-inhibiting drugs ...
Cronin-Fenton, Deirdre P, Damkier, Per
openaire   +4 more sources

Rapid Detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 Alleles by Tetra-Primer PCR and of the CYP2D6*5 Allele by Multiplex Long PCR [PDF]

Clinical Chemistry, 2000
Abstract Background: Interindividual differences in CYP2D6 activity range from total absence of metabolism of certain drugs to ultrafast metabolism and can produce adverse effects or lack of therapeutic effect under standard therapy. Several mutations have been described in the CYP2D6 gene that abolish CYP2D6 activity.
Hersberger, Martin, Marti-Jaun, Jacqueline, Rentsch, Katharina, Hänseler, Edgar   +3 more
openaire   +3 more sources

Physicochemical and biopharmaceutical characterization of new sulfonamide derivatives of gallic acid

British Journal of Pharmacy, 2022
Gallic acid (GA) is known for its antioxidant activity which is restricted due to its low oral permeability. In this project the carboxylic group of (GA) was substituted with sulfonamide group and hydroxyl groups were methylated which resulted ...
Dania Hussein Alhyari, Helen Sheldrake , Sriharsha Kantamneni, Mohammad Isreb, Shohreh Jafarinejad Soumehsaraei , William Martin, Nidal Qinna, Krzysztof Paluch   +7 more
doaj   +1 more source

A frequent CYP2D6 variant promotes skipping of exon 3 and reduces CYP2D6 protein expression in human liver samples

Frontiers in Pharmacology, 2023
CYP2D6 is one of the most polymorphic drug-metabolizing enzymes in the liver. While genetic CYP2D6 variants serve as clinical biomarkers to predict CYP2D6 activity, large inter-person variability in CYP2D6 expression remains unaccounted for.
Joseph M. Collins, Hannah Lester, Samia Shabnaz, Danxin Wang   +3 more
doaj   +1 more source

CYP2D6 gene polymorphism effect on central hemodynamic parameters in patients with portal hypertension taking propranolol

Медицинский совет, 2022
Introduction. Despite the huge number of modern recommendations for the treatment of patients with liver cirrhosis, there is still no clear scheme for prescribing non-selective beta-blockers.Aim. To evaluate effect of polymorphic markers CYP2D6*3, CYP2D6*
A. I. Parusov, I. D. Loranskaya, K. A. Akmalova, Zh. A. Sozaeva, O. L. Turkina, M. S. Zastrozhin, D. A. Sychev   +6 more
doaj   +1 more source

Novel single nucleotide polymorphisms in the CYP2D6 gene associated with CYP2D6*2 and/or CYP2D6*10 alleles

Drug Metabolism and Pharmacokinetics, 2002
Novel single nucleotide polymorphisms (SNPs) were found in introns 1, 3, 4, 5, and 7 of the gene encoding cytochrome (CYP) 2D6 in 90 Japanese subjects. Some of these SNPs were associated with C2850T and/or C100T, which are key SNPs for CYP2D6(*)2 and CYP2D6(*)10, respectively.
SOYAMA, Akiko, SAITO, Yoshiro, KOMAMURA, Kazuo, UENO, Kazuyuki, KAMAKURA, Shiro, OZAWA, Shogo, SAWADA, Jun-ichi   +6 more
openaire   +2 more sources

The Effect of Polymorphisms in the CYP2D6 and CYP2C9 Genes on the Clinical Efficacy of Tramadol and Ketorolac When Using the Accelerated Recovery Protocol in Patients With Uncomplicated Acute Calculous Cholecystitis Who Underwent Cholecystectomy

Неотложная медицинская помощь, 2020
Relevance. One of the key components of the accelerated recovery protocols (ARP), in addition to minimizing the surgical approach, is an adequate postoperative analgesia.
A. A. Muradyan, D. A. Blagovestnov, D. A. Sychev, P. A. Yartsev, M. L. Rogal, L. N. Kerimova, V. T. Koroshvili, I. A. Yepifanova   +7 more
doaj   +1 more source

CYP2D6 Gene Polymorphisms and Variable Metabolic Activity in Schizophrenia Patients of Han and Tibetan Populations

Neuropsychiatric Disease and Treatment, 2022
Yong-Hang Li,1,* Wei Huang,1,* Man-Yu Xiao,2 Shi-Qing Huang,1 Hui Chen,1 Zai-Fang Li,1 Xue-Song Li,1 Yong Cheng1,2 1The Third People’s Hospital of Foshan, Foshan, Guangdong, People’s Republic of China; 2Center on Translational Neuroscience ...
Li YH, Huang W, Xiao MY, Huang SQ, Chen H, Li ZF, Li XS, Cheng Y   +7 more
doaj  

CYP2D6 in the Brain: Potential Impact on Adverse Drug Reactions in the Central Nervous System—Results From the ADRED Study

Frontiers in Pharmacology, 2021
Cytochrome P450 (CYP) 2D6 is a polymorphic enzyme expressed in the central nervous system (CNS), important in drug metabolism and with a potentially constitutive role in CNS function such as vigilance.
Katja S. Just, Harald Dormann, Mathias Freitag, Marlen Schurig, Miriam Böhme, Michael Steffens, Catharina Scholl, Thomas Seufferlein, Ingo Graeff, Matthias Schwab, Matthias Schwab, Matthias Schwab, Julia C. Stingl   +12 more
doaj   +1 more source

CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6∗10 on Interindividual Variation in a Chinese Population

Frontiers in Pharmacology, 2017
Purpose: Asian populations have around 40–60% frequency of reduced function allele CYP2D6∗10 compared to 1–2% in Caucasian populations. The wide range of CYP2D6 enzyme activities in subjects with the CYP2D6∗10 variant is a big concern for clinical ...
Pei Hu, Rui Chen, Xin Zheng
doaj   +1 more source